CRM
49
5
URBN
70
7
PPG
64
3
CAG
47
3
NEM
61
-2
L
50
-5
DNB
24
2
CTAS
55
2
EL
52
4
AMT
41
-4
ILMN
38
2
VLO
33
-2
JNJ
26
2
BWA
50
9
AVGO
52
8
KEY
50
11
CMG
72
-2
BMY
35
2
ROST
52
2
RIG
50
4
CRM
49
5
URBN
70
7
PPG
64
3
CAG
47
3
NEM
61
-2
L
50
-5
DNB
24
2
CTAS
55
2
EL
52
4
AMT
41
-4
ILMN
38
2
VLO
33
-2
JNJ
26
2
BWA
50
9
AVGO
52
8
KEY
50
11
CMG
72
-2
BMY
35
2
ROST
52
2
RIG
50
4
Financhill
Back

Iovance Biotherapeutics 10K Form

Sell
41

IOVA
Iovance Biotherapeutics

Last Price:
11.95
Seasonality Move:
6.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive IOVA News And Ratings

See the #1 stock for the next 7 days that we like better than IOVA

IOVA Financial Statistics

Sales & Book Value

Annual Sales: $1.19M
Cash Flow: $-87.5M
Price / Cash Flow: 0
Annual Sales: $2.28
Price / Book: 5.56

Profitability

EPS (TTM): -1.88000
Net Income (TTM): $-444.04M
Gross Margin: $-9.57M
Return on Equity: 0%
Return on Assets: 0%

Iovance Biotherapeutics Earnings Forecast

Key Iovance Biotherapeutics Financial Ratios

  • The Gross Profit Margin over the past 16 years for IOVA is -804.54%.
  • The Selling, General & Administrative Expenses for IOVA have been equal to 8,992.09% of Gross Profit Margin.
  • The Research & Development expenses have been 28,938.35% of Revenue.
  • The Interest Expense is -73.16% of Operating Income.
  • Per Share Earnings over the last 16 years have been positive in 7 years.

Iovance Biotherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: IOVA
CUSIP: 462260
Website: iovance.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.79
Quick Ratio: 2.54

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

IOVA Technical Analysis vs Fundamental Analysis

Sell
41
Iovance Biotherapeutics (IOVA) is a Sell

Is Iovance Biotherapeutics a Buy or a Sell?